// App-Quantinova.ai

3081 : Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Researchers

Presenter

  • Charlotte K Brierley

Principal Investigators

  • Alba Rodriguez-Meira

  • Matthew Bashton

  • Angela Hamblin

  • Rachel S Fletcher

  • Sonia Fox

  • Charlotte Gaskell

  • Aimee Jackson

  • Jennifer O'Sullivan

  • Lauren C Murphy

  • Nikolaos Sousos

  • Amir Enshaei

  • Claire Harrison

  • Mark W. Drummond

  • Steve Knapper

  • Bethan Psaila

  • Adam J. Mead

Medical Centers

  • Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  • IGF Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • The Hub for Biotechnology in the Built Environment, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Wolfson Childhood Cancer Research Centre,Newcastle University,Newcastle upon Tyne,Vereinigtes Königreich

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

  • Beaston Inst for Cancer Center, Glasgow, United Kingdom

  • Gartnavel General Hospital, Glasgow, United Kingdom

  • Institute of Cancer & Genetics, Cardiff University, Cardiff, Wales, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Cluster of Differentiation 206

  • Calreticulin

  • Enhancer of zeste homolog 2

  • ETV6-RUNX1

  • Isocitrate dehydrogenase 1

  • Tet methylcytosine dioxygenase 2

  • Tumor protein p53

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Ruxolitinib phosphate

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved